This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
June ISM manufacturing index witnessed the best gain in the four months amid trade war anxieties. This call for bets on top-ranked manufacturing stocks.
IRET.PR IRET.PRCL IR.WI IRET.PRC SKUFF TACO IRET.PRB WIRE KAMN IRET TKR ZBRA TWNK TACOW IR WRD INGERRAND DHR 500210 MO
In its first week of trading, business intelligence software company Domo has seesawed, rising sharply on its first day of trading and then giving up all of those gains.
ZUO APRN TNTR DATA DOCU CRM ADBE AVLR SAP DBX T DOMO MSFT DHR ORCL EBAY SNAP
Designed to provide broad exposure to the Industrials - Water segment of the U.S. equity market, the Guggenheim S&P Global Water Index ETF (CGW - Free Report) is a passively managed exchange traded fund launched on 05/14/2007.
AWK XYL FIDU ICHR DHR
June 26 (Reuters) - General Electric Co’s plan to divest $20 billion worth of assets may have bankers excited about contacting potential buyers, breaking off other big chunks of the conglomerate, and creating an M&A bonanza.
BHI SLB GEC GE TMO GNE SCL SLB DHR
(Reuters) - General Electric Co’s plan to divest $20 billion worth of assets may have bankers excited about contacting potential buyers, breaking off other big chunks of the conglomerate, and creating an M&A bonanza.
BHI SLB GEC GE TMO GNE SCL SLB DHR
On Jun 20, we issued an updated research report on premium diversified operations company — Danaher Corporation (DHR - Free Report) . The company currently carries a Zacks Rank #4 (Sell) and holds a VGM Score of D. Rising cost of sales remains a major cause of concern for Danaher. The company’s cost of sales flared up 13.3% and 7.8%, year over year, in 2016 and 2017, respectively. Notably, the same rose 9.
RAVN SSUMF CR SSUMY DHR
Cantel Medical (CMD) is a high quality growth company that is likely to significantly grow its earnings over the next 5 years. The company supplies a diverse set of very stable and growing medical end-markets. The company has a strong track record of generating organic growth but has also demonstrated an ability to grow inorganically through bolt-on acquisitions.
CMN CMD DHR CNSWF
8h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
9h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to DHR / Danaher Corp. on message board site Silicon Investor.
|Danaher Corp. (DHR)|
as of ET